Etodolac

• CAT Number: A000395
• CAS Number: 41340-25-4
• Molecular Formula: C17H21NO3
• Molecular Weight: 287.35
• Purity: ≥95%
• Synonyms: Etodolic acid; 41340-25-4; Lodine; Ultradol; Lodine XL
• Target: COX
• Solubility: Soluble in DMSO > 10 mM
• Storage: -20°C
• IUPAC Name: 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid
• InChI: 1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)
• InChIKey: NNYBQONXHNTVIJ-UHFFFAOYSA-N
• SMILES: CCC1=CC=CC2=C1NC3=C2CCOC3(CC)CC(=O)O

Etodolac (Cat No.: A000395) is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain and reduce inflammation in conditions like osteoarthritis, rheumatoid arthritis, and acute musculoskeletal disorders. It selectively inhibits cyclooxygenase-2 (COX-2) more than COX-1, which may lower the risk of gastrointestinal side effects compared to traditional NSAIDs. Etodolac is available in immediate and extended-release oral formulations. Common side effects include dyspepsia, dizziness, and headache. Caution is advised in patients with cardiovascular disease, kidney impairment, or a history of gastrointestinal bleeding.

Reference

1: Zhang X, Li Q, Ye M, Zhao Z, Sun J, Yang X, Pan W. Preparation,
Characterization and In Vitro / In Vivo Evaluation of Oral Time-Controlled
Release Etodolac Pellets. AAPS PharmSciTech. 2017 Sep 15. doi:
10.1208/s12249-017-0873-3. [Epub ahead of print] PubMed PMID: 28917009.

2: de Miranda Silva C, Rocha A, Tozatto E, da Silva LM, Donadi EA, Dalla Costa T,
Lanchote VL, Schmidt S, Bulitta JB. Development of an Enantioselective and
Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model
for Etodolac. AAPS J. 2017 Sep 5. doi: 10.1208/s12248-017-0138-9. [Epub ahead of
print] PubMed PMID: 28875479.

3: Taneja S, Kumar P, Rathi S, Duseja A, Singh V, Dhiman RK, Chawla YK. Acute
Liver Failure Due to Etodolac, a Selective Cycloxygenase- 2 (COX -2) Inhibitor
Non-Steroidal Anti-Inflammatory Drug Established by RUCAM-Based Causality
Assessment. Ann Hepatol. 2017 Sep-Oct;16(5):818-821. doi:
10.5604/01.3001.0010.2829. PubMed PMID: 28809737.

4: Vergili I, Gencdal S. Removal of Organic Matter and Etodolac from
Pharmaceutical Industry Wastewater by PAC Adsorption. Water Environ Res. 2017 Jul
1;89(7):641-651. doi: 10.2175/106143017X14902968254520. PubMed PMID: 28641674.

5: Ali I, Suhail M, Alothman ZA, Alwarthan A. Chiral separation and modeling of
baclofen, bupropion, and etodolac profens on amylose reversed phase chiral
column. Chirality. 2017 Jul;29(7):386-397. doi: 10.1002/chir.22717. PubMed PMID:
28608452.

6: Salah S, Mahmoud AA, Kamel AO. Etodolac transdermal cubosomes for the
treatment of rheumatoid arthritis: ex vivo permeation and in vivo pharmacokinetic
studies. Drug Deliv. 2017 Nov;24(1):846-856. doi: 10.1080/10717544.2017.1326539.
PubMed PMID: 28535740.

7: Liao KF, Cheng KC, Lin CL, Lai SW. Etodolac and the risk of acute
pancreatitis. Biomedicine (Taipei). 2017 Mar;7(1):4. doi:
10.1051/bmdcn/2017070104. Epub 2017 Mar 3. PubMed PMID: 28474580; PubMed Central
PMCID: PMC5439338.

8: Sherje AP, Kulkarni V, Murahari M, Nayak UY, Bhat P, Suvarna V, Dravyakar B.
Inclusion Complexation of Etodolac with Hydroxypropyl-beta-cyclodextrin and
Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies.
Mol Pharm. 2017 Apr 3;14(4):1231-1242. doi: 10.1021/acs.molpharmaceut.6b01115.
Epub 2017 Mar 1. PubMed PMID: 28248111.

9: Song ID, Kang JS, Kim HJ, Kim SM, Zhao DX, Kim SH, Chun MY, Lee KH.
Quantification of Etodolac in Human Plasma for Pharmacokinetics and
Bioequivalence Studies in 27 Korean Subjects. Drug Metab Lett.
2017;10(4):286-294. doi: 10.2174/1872312811666170116151004. PubMed PMID:
28093968.

10: Mohammed AM, Faisal W, Saleh KI, Osman SK. Self-Assembling Organogels Based
on Pluronic and Lecithin for Sustained Release of Etodolac: In Vitro and In Vivo
Correlation. Curr Drug Deliv. 2017;14(7):926-934. doi:
10.2174/1567201813666160902151514. PubMed PMID: 27593184.